- Senate passes Drug Quality and Security Act
- Study from NCPA sheds new light on med synchronization programs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Q&A: Genetic profiling with Dr. Anita Goel of Nanobiosym
ST. LOUIS — K-V Pharmaceutical announced Wednesday that the Food and Drug Administration extended its Prescription Drug User Fee Act action date to April 13 for a drug under development for preventing preterm birth.
K-V, which acquired the injected drug Gestiva (hydroxyprogesterone caproate) from Hologic in 2008, said Hologic originally had been told the FDA would take action Thursday.
K-V said it was confident the drug would receive approval and that the FDA would take action on or before the new PDUFA date.